Tirzepatide

Tirzepatide’s benefits fade for most: Weight and health markers rebound after withdrawal, study finds

December 1, 2025 / Research update / InnovateMed Author / Tirzepatide

by Justin Jackson, Medical Xpress edited by Sadie Harley, reviewed by Robert Egan Editors’ notes Credit: Unsplash/CC0 Public Domain Eli Lilly and Company, along with partner institutions in the US and United Kingdom, describe how short-term pharmacologic intervention does not appear to have lasting effects for most tirzepatide patients. People with obesity who lost weight on tirzepatide often […]

Tirzepatide’s benefits fade for most: Weight and health markers rebound after withdrawal, study finds Read More »

First Randomized Trial of Tirzepatide in T1D Shows Benefits

September 29, 2025 / Research update / InnovateMed Author / Tirzepatide

VIENNA — Tirzepatide was associated with improvements in body weight and body composition, and with lower insulin doses, in the first-ever randomized controlled trial (RCT) of the drug in people with type 1 diabetes (T1D). “Tirzepatide may play a role in weight management in adults with T1D and obesity, even at low doses,” Jennifer R. Snaith, MD, of the Garvan Institute of

First Randomized Trial of Tirzepatide in T1D Shows Benefits Read More »

Tirzepatide Tops TRT for Men With Hypogonadism and Obesity

August 11, 2025 / Clinical Practice / InnovateMed Author / Hypogonadism, obesity, Tirzepatide

San Francisco — Tirzepatide is a promising treatment for metabolic hypogonadism in men with obesity, new research suggested. In a study of 83 men with obesity, functional hypogonadism, and insulin resistance, those treated with the dual glucose-dependent insulinotropic peptide and glucagon-like peptide 1 (GLP-1) receptor agonist tirzepatide for 2 months had greater weight loss, increased

Tirzepatide Tops TRT for Men With Hypogonadism and Obesity Read More »

– Tirzepatide Outperforms Semaglutide on Combined T2D Goals

August 3, 2025 / Clinical Practice / InnovateMed Author / Tirzepatide

Patients treated with tirzepatide have a significantly increased likelihood of attaining combined key therapeutic targets in the control of type 2 diabetes (T2D) compared with semaglutide, a post hoc analysis of the phase 3 SURPASS-2 trial showed. “In this post hoc analysis, we showed that tirzepatide was superior to semaglutide in achieving standard and intensive

– Tirzepatide Outperforms Semaglutide on Combined T2D Goals Read More »

Tirzepatide Outperforms Semaglutide on Combined T2D Goals –

July 23, 2025 / Research update / InnovateMed Author / semaglutide, Tirzepatide

Tirzepatide Outperforms Semaglutide on Combined T2D Goals – Read More »

Eye Complications Found With Use of Semaglutide, Tirzepatide

June 17, 2025 / Research update / InnovateMed Author / Eye Complications, semaglutide, Tirzepatide

TOPLINE: At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic optic neuropathy (NAION), according to a case series. Researchers hypothesize that rapid correction of hyperglycemia induced by these drugs may be associated with eye disorders. METHODOLOGY: Researchers reported on

Eye Complications Found With Use of Semaglutide, Tirzepatide Read More »